Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Next Previous
Trial Profile

Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Givinostat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions

Most Recent Events

  • 31 Jan 2012 Actual patient number (1) added as reported by ClinicalTrials.gov.
  • 31 Jan 2012 Planned end date changed from 1 Dec 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov.
  • 31 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top